Skip to main content

Table 3 Logistic regression models predicting overall change in CD4 + T cell count of adults during ART

From: Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children

Variables aRisk of non-response bRisk of failure to attain >200 CD4 cell
   OR (95% CI) P value OR (95% CI) P value
Sex Female 0.2 (0.65-0.658) 0.08 6.5  
  Male 0.4 (0.16-1.33) 0.150   
Age (years) <29   0.76   0.52
  30-39 1.68 (0.401-7.09) 0.47 14.0 (1.62-122.7) 0.160
  ≥40 1.17 (0.32-4.21) 0.81 1.88 (0.60-5.90) 0.278
WHO Clinical Stage I I   0.69   0.4
  II 0.154 (0.007-3.57) 0.244 0.038 (0.002-0.894) 0.045
  III 0.346 (0.027-4.418 0.414 0.769 (0.043-13.866) 0.8
  IV 0.359 (0.043-3.013) 0.345 0.325 (0.039-2.7) 0.32
Haematocrit value < 37% 3.0   3.0  
  ≥ 37% 2.54 (0.848-7.514) 0.096 2.16 (0.751-6.253) 0.153
ART regimen      
  3TC + d4T + NVP 1.66 (0.349-7.9) 0.542 4.857 (0.974-24.227) 0.054
  3TC + d4T + EFV 1.87 (0.36-9.64) 0.450 2.286 (0.50-10.44) 0.286
  3TC + AZT + NVP 6.00 (0.53-67.27) 0.146 2.667 (0.463-15.35) 0.272
  3TC + AZT + EFV   0.54   0.288
CD4+ T cell count <50   0.313   0.99
  50-99 2.00 (0.174-22.94) 0.578 0.578 0.99 (0.00-) 0.9
  100-199 9.20 (0.91-93.02) 0.060 0.060 0.99 (0.00-) 0.9
  200-349 1.68 (0.436-6.47) 0.451 0.451 0.99 (0.00-) 0.9
  1. a Risk of immunological non-response (an increase of <50 cells/mm 3 at 12 months).
  2. b Failure to attain an absolute CD4 + cell count of ≥ 200 cells/mm 3 after 48 weeks ART).